378 707

Cited 10 times in

Antiviral efficacies of currently available rescue therapies for multidrug-resistant chronic hepatitis B

DC Field Value Language
dc.contributor.author전재윤-
dc.contributor.author한광협-
dc.contributor.author김경식-
dc.contributor.author김도영-
dc.contributor.author김범경-
dc.contributor.author김승업-
dc.contributor.author김자경-
dc.contributor.author박미성-
dc.contributor.author박준용-
dc.contributor.author안상훈-
dc.date.accessioned2014-12-18T10:00:04Z-
dc.date.available2014-12-18T10:00:04Z-
dc.date.issued2013-
dc.identifier.issn2287-2728-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/89229-
dc.description.abstractBackground/Aims: The incidence of multidrug-resistant (MDR) chronic hepatitis B (CHB) during sequential lamivudine (LAM) and adefovir dipivoxil (ADV) treatment is increasing. We investigated the antiviral efficacies of various rescue regimens in patients who failed sequential LAM-ADV treatment. Methods: Forty-eight patients (83.3% of whom were HBeAg-positive) who failed sequential LAM-ADV treatment were treated with one of the following regimens: entecavir (ETV) (1 mg) monotherapy (n=16), LAM+ADV combination therapy (n=20), or ETV (1 mg)+ADV combination therapy (n=12). All patients had confirmed genotypic resistance to both LAM and ADV and were evaluated every 12 weeks. Results: The baseline characteristics and treatment duration did not differ significantly among the study groups. During the treatment period (median duration: 100 weeks), the decline of serum HBV DNA from baseline tended to be greatest in the ETV+ADV group at all-time points (week 48: -2.55 log10 IU/mL, week 96: -4.27 log10 IU/mL), but the difference was not statistically significant. The ETV+ADV group also tended to have higher virologic response rates at 96 weeks compared to the ETV monotherapy or LAM+ADV groups (40.0% vs. 20.0% or 20.0%, P=0.656), and less virologic breakthrough was observed compared to the ETV monotherapy or LAM+ADV groups (8.3% vs. 37.5% or 30.0%; P =0.219), but again, the differences were not statistically significant. HBeAg loss occurred in one patient in the ETV+ADV group, in two in the ETV monotherapy group, and in none of the LAM+ADV group. The safety profiles were similar in each arm. Conclusions: There was a nonsignificant tendency toward better antiviral efficacy with ETV+ADV combination therapy compared to LAM+ADV combination therapy and ETV monotherapy for MDR CHB in Korea, where tenofovir is not yet available.-
dc.description.statementOfResponsibilityopen-
dc.relation.isPartOfCLINICAL AND MOLECULAR HEPATOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdenine/analogs & derivatives-
dc.subject.MESHAdenine/therapeutic use-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAntiviral Agents/therapeutic use*-
dc.subject.MESHDNA, Viral/blood-
dc.subject.MESHDrug Resistance, Viral-
dc.subject.MESHDrug Therapy, Combination-
dc.subject.MESHFemale-
dc.subject.MESHFollow-Up Studies-
dc.subject.MESHGenotype-
dc.subject.MESHGuanine/analogs & derivatives-
dc.subject.MESHGuanine/therapeutic use-
dc.subject.MESHHepatitis B e Antigens/blood-
dc.subject.MESHHepatitis B virus/genetics-
dc.subject.MESHHepatitis B, Chronic/drug therapy*-
dc.subject.MESHHumans-
dc.subject.MESHLamivudine/therapeutic use-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHOrganophosphonates/therapeutic use-
dc.subject.MESHTreatment Outcome-
dc.titleAntiviral efficacies of currently available rescue therapies for multidrug-resistant chronic hepatitis B-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorMi Sung Park-
dc.contributor.googleauthorBeom Kyung Kim-
dc.contributor.googleauthorKyung Sik Kim-
dc.contributor.googleauthorJa Kyung Kim-
dc.contributor.googleauthorSeung Up Kim-
dc.contributor.googleauthorJun Yong Park-
dc.contributor.googleauthorDo Young Kim-
dc.contributor.googleauthorOidov Baartarkhuu-
dc.contributor.googleauthorKwang Hyub Han-
dc.contributor.googleauthorChae Yoon Chon-
dc.contributor.googleauthorSang Hoon Ahn-
dc.identifier.doi10.3350/cmh.2013.19.1.29-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA04268-
dc.contributor.localIdA00299-
dc.contributor.localIdA00487-
dc.contributor.localIdA00654-
dc.contributor.localIdA00852-
dc.contributor.localIdA01462-
dc.contributor.localIdA01675-
dc.contributor.localIdA02226-
dc.contributor.localIdA03544-
dc.contributor.localIdA00385-
dc.relation.journalcodeJ00557-
dc.identifier.eissn2287-285X-
dc.identifier.pmid23593607-
dc.subject.keywordAdefovir-
dc.subject.keywordEntecavir-
dc.subject.keywordHepatitis B-
dc.subject.keywordHepatitis B virus-
dc.subject.keywordMultidrug resistance-
dc.contributor.alternativeNameChon, Chae Yoon-
dc.contributor.alternativeNameHan, Kwang Hyup-
dc.contributor.alternativeNameKim, Kyung Sik-
dc.contributor.alternativeNameKim, Do Young-
dc.contributor.alternativeNameKim, Beom Kyung-
dc.contributor.alternativeNameKim, Seung Up-
dc.contributor.alternativeNameKim, Ja Kyung-
dc.contributor.alternativeNamePark, Mi Sung-
dc.contributor.alternativeNamePark, Jun Yong-
dc.contributor.alternativeNameAhn, Sang Hoon-
dc.contributor.affiliatedAuthorHan, Kwang Hyup-
dc.contributor.affiliatedAuthorKim, Kyung Sik-
dc.contributor.affiliatedAuthorKim, Beom Kyung-
dc.contributor.affiliatedAuthorKim, Seung Up-
dc.contributor.affiliatedAuthorKim, Ja Kyung-
dc.contributor.affiliatedAuthorPark, Mi Sung-
dc.contributor.affiliatedAuthorPark, Jun Yong-
dc.contributor.affiliatedAuthorAhn, Sang Hoon-
dc.contributor.affiliatedAuthorChon, Chae Yoon-
dc.contributor.affiliatedAuthorKim, Do Young-
dc.rights.accessRightsfree-
dc.citation.volume19-
dc.citation.number1-
dc.citation.startPage29-
dc.citation.endPage35-
dc.identifier.bibliographicCitationCLINICAL AND MOLECULAR HEPATOLOGY, Vol.19(1) : 29-35, 2013-
dc.identifier.rimsid34467-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.